An observational study in Blood Pressure, Low, sponsored by Heidelberg University. Status unknown. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-19.
Sponsored by Heidelberg University · Observational
The induction of anesthesia is one of the most critical situations for high-risk-patients undergoing major surgery. For several reasons, it is crucial to maintain adequate blood pressure and cardiac output during this phase.
This observational study aims to find out if the choice of the induction agent has a major impact on blood pressure and the use of antihypotensive drugs during the induction and the surgical procedure in heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD).
5,701 studies on the registry are indexed under Heart Failure; 1,220 are open to participants now.
This study's planned enrollment of 50 is below the median of 200 across 1,679 observational studies indexed under Heart Failure.
Browse Heart Failure studies →Heidelberg University is the lead sponsor of 279 studies on the registry; 17 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with terminal heart failure which are scheduled for implantation of a left ventricular assist device (LVAD)
Exclusion Criteria:
High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is etomidate.
Drug: Etomidate
High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is midazolam.
Drug: Midazolam
High-risk heart-failure patients undergoing the implantation of a left ventricular assist device (LVAD). The induction agent is sevoflurane.
Drug: Sevoflurane
Use of etomidate during induction as decided by attending anesthesiologist
Use of midazolam during induction as decided by attending anesthesiologist
Use of sevoflurane during induction as decided by attending anesthesiologist
Post-Induction hypotension
The incidence of hypotension in the first 30 minutes after the induction of anesthesia
Time frame: First 30 minutes after induction of anesthesia
Antihypotensive drugs after induction
Use of antihypotensive drugs during the first 30 minutes after induction of anesthesia
Time frame: First 30 minutes after induction of anesthesia
Antihypotensive drugs during the procedure
Use of antihypotensive drugs during the procedure
Time frame: Begin of the procedure until end of the procedure
Length of stay on the intensive care unit (ICU)
The time the patient has to be treated on intensive care unit after the procedure (in hours) before submission.
Time frame: After the procedure and transport to intensive care unit, total time in hours until submission from I. Expected time frame is 48 to 96 hours.CU
Delirium
Diagnosis of postoperative delirium
Time frame: First 24 hours after the end of the procedure
Kidney
Occurrence of acute kidney failure as defined by Kidney Disease: Improving Global Outcomes (KDIGO)
Time frame: First 28 days after procedure
Mortality
Mortalitiy in the first 28 days after the procedure
Time frame: First 28 days after procedure
No study locations are listed for this record.
This study is status unknown, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Heidelberg University